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I. INTRODUCTION
In the products liability and toxic tort arena, plaintiffs often
face exceedingly difficult evidentiary obstacles in their quest to
prove that defendants' conduct proximately caused their injuries.
Toxic chemicals or defective pharmaceuticals may not cause a sig-
nature disease, thus leaving plaintiffs with the burden of proving
that their disease was caused by defendants' product, and not some
other material or product to which they were exposed. The long
latency period of many toxic substances requires plaintiffs to estab-
t Arvin Maskin is a Partner, Konrad L. Cailteux is Of Counsel, and Joanne
M. McLaren is an Associate at Weil, Gotshal & Manges LLP in New York, New
York, where they specialize in products liability, mass tort and complex litigation.
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lish a causal connection between the onset of illness and defen-
dants' conduct of perhaps several decades in the past. Such mas-
sive time lapses obviously make facts harder to gather, witnesses
more likely to be unavailable, and any causal chain intuitively more
tenuous.
Reacting to these realities, plaintiffs have sought, and courts
have created, less traditional causes of action or remedies, which
ease plaintiffs' burden of proof. One such example is the claim for
medical monitoring expenses. Courts have shown increased recep-
tivity to medical monitoring claims, and plaintiffs have reacted by
routinely seeking medical monitoring costs. Indeed, a medical
monitoring claim appears to have become an almost inevitable fea-
ture of any cause of action arising from chemical exposure or al-
legedly defective pharmaceutical or medical products.
A claim for medical monitoring expenses is intended to fi-
nance diagnostic examinations for presently healthy plaintiffs who
have been exposed to a toxic substance, in the hope that early de-
tection and treatment of the disease will be beneficial.3 Generally,
plaintiffs need not prove that they are presently injured, or even
that they will likely sustain an injury in the future. Rather, in order
to prevail, plaintiffs must only demonstrate that the defendants'
conduct exposed them to a substance which increased their risk of
adverse health effects, that a diagnostic test exists which can detect
the disease, and that treatment is available for the disease of which
onset is feared.
With its lower standards of proof, a medical monitoring award
often represents plaintiffs' strongest chance of success. Thus, in fu-
ture cases involving toxic chemicals, pharmaceuticals or medical
devices, we should expect to see such claims whenever a colorable
argument of their necessity can be advanced.
1. For example, the average latency periods for various carcinogenic sub-
stances are: arsenic, 25 years; tar, 20-24 years; radiation, 20-30 years; and asbestos,
18 years. Allan T. Slagel, Medical Surveillance Damages: A Solution to the Inadequate
Compensation of Toxic Tort Victims, 63 IND. L.J. 849, 852 n.15 (1988) (citing 5B Laz-
yers' Medical Cyclopedia of Personal Injuries and Allied Specialties, § 38.46h (3d ed.
1986)).
2. E.g., In re Diet Drugs Prods. Liab. Litig., No. 98-20626, 1999 U.S. Dist.
LEXIS 13228, at *3 (E.D. Pa. Aug. 26, 1999) (discussing medical costs from expo-
sure to diet drugs); Day v. NLO, 851 F. Supp. 869, 876 (S.D. Ohio 1994) (discuss-
ing medical costs from exposure to radiation); Bower v. Westinghouse Elec. Co.,
522 S.E.2d 424, 427 (W. Va. 1999) (discussing medical costs from exposure to light
bulbs).
3. Ayers v. Jackson Township, 525 A.2d 287, 308 (N.J. 1987).
[Vol. 27:1
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II. THE HISTORICAL DEVELOPMENT OF MEDICAL MONITORING
AWARDS
The origins of medical monitoring awards can be traced back
to Friends for All Children v. Lockheed Aircraft Corp.,4 where they were
first permitted, albeit in a highly regulated manner. The Friends ac-
tion was brought on behalf of a group of 149 Vietnamese orphans
who had survived the decompression and crash of the Lockheed
aircraft transporting them from Saigon to the United States, where
they were to meet their adoptive parents.5 An organization, Friends
for All Children, held itself out as the legal guardian of the survi-
vors, and sought the costs of the diagnostic testing which it claimed
the children would need to determine whether or not they were
6suffering from neurological disorders.
The district court granted plaintiffs partial summary judgment
on the issue of defendant's liability for the crash, and ordered
Lockheed to create a fund from which the diagnostic expenses
plaintiffs sought could be disbursed. On appeal, the court first
addressed whether or not the District of Columbia would permit a
cause of action for diagnostic examinations notwithstanding the
absence of proof of present injury. The court concluded that such
a cause of action was viable, providing an analogy, which has since
been used by many courts as a shorthand justification for medical
monitoring costs, absent injury:
Jones is knocked down by a motorbike which Smith
is riding through a red light. Jones lands on his head
with some force. Understandably shaken, Jones enters a
hospital where doctors recommend that he undergo a
battery of tests to determine whether he has suffered any
internal head injuries. The tests prove negative, but
Jones sues Smith solely for what turns out to be the sub-
stantial cost of the diagnostic examinations.
From our example, it is clear that even in the ab-
4. 746 F.2d 816, 824-28 (D.C. Cir. 1984).
5. Id. at 819-20.
6. Id.
7. Id. at 820, 822.
8. Id. at 824-25.
9. E.g., Friends, 746 F.2d 816, 825 (D.C. Cir. 1984); Hansen v. Mountain Fuel
Supply Co., 858 P.2d 970, 977-78 (Utah 1993) (approving Friends analysis); Bower,
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sence of physical injury Jones ought to be able to recover
the cost for the various diagnostic examinations proxi-
mately caused by Smith's negligent action. A cause of ac-
tion allowing recovery for the expense of diagnostic ex-
aminations recommended by competent physicians will,
in theory, deter misconduct, whether it be negligent mo-
torbike riding or negligent aircraft manufacture. ... The
motorbike rider, through his negligence, caused the
plaintiff, in the opinion of medical experts, to need spe-
cific medical services-at a cost that is neither inconse-
quential nor of a kind that the community generally ac-
cepts as part of the wear and tear of daily life. Under
these principles of tort law, the motorbiker should pay.10
The court affirmed the decision below, finding that the irrepa-
rable injury that may befall plaintiffs outweighed the danger of
hardship to defendant." Indeed, the district court had placed sev-
eral important checks on the fund, to minimize hardship to Lock-
heed, and to verify that the funds were used for legitimate pur-12
poses. Most importantly, a voucher system was envisioned,
whereby a child's guardian would submit a voucher delineating ex-
penses incurred, at which time Lockheed could object to reim-
bursement for the procedure undergone." A science panel, con-
sisting of professionals such as psychologists, psychiatrists and
neurologists, was to provide input as to what future testing a child
should undergo.14 A doctor was to review each patient's medical
records, to determine which tests the child had already undergone,
thus ensuring that defendant would not be required to pay for re-
dundant testing.
15
Significantly, relief was awarded only to the French plaintiffs,
the district court finding that the public health* systems of all the
other countries where plaintiffs resided would pay for any medical
examinations required. Thus, the district court refused to permit
recovery to those who would incur no out-of-pocket expenses."
10. Friends, 746 F.2d at 825.
11. Id. at 826-27.
12. Id. at 823.
13. Id.
14. Id.
15. Id. at 835 & n.34.
16. Friends for All Children v. Lockheed Aircraft Corp., 746 F.2d 816, 822 n.
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Furthermore, the fund proceeds were to be placed in an interest-
bearing account, and after completion of the examinations, all
money not expended was to be returned to Lockheed. 
s
Although Friends was not a products liability or toxic tort case,
it did not take long for the rationale presented therein to be ex-
tended to the products liability and toxic tort context. In the semi-
nal case of Ayers v. Jackson Township,'9 plaintiffs brought suit after
consuming well water contaminated by toxic pollutants leaching
from a landfill operated by the township.2 A jury awarded the
plaintiff class over $8 million to cover future costs of diagnostic test-
ing for cancer and other diseases that plaintiffs allegedly were at
21increased risk of contracting as a result of the exposure.
On appeal, the Appellate Division concluded that the scien-
tific evidence could not "rule out the probability that such increase
is so microscopically small as to be meaningless. 22 Thus, the court
set aside the medical monitoring award, holding that, 'Without
some quantifying guidance [as to increased risk], it becomes im-
possible to say that defendant has so significantly increased the
'reasonable probability' that any of the plaintiffs will develop cancer
so as to justify imposing upon defendant the financial burden of
lifetime medical surveillance....
The NewJersey Supreme Court reinstated the award, finding
that diagnostic testing may be medically necessary, and thus com-
pensable, even where plaintiffs' risk of disease is only slightly higher
than for the general population,24 setting the stage for the explo-
sion of medical monitoring cases which would follow in recent
years.
III. ARGUMENTS FOR MEDICAL MONITORING DAMAGES
Building on Friends and Ayers, plaintiffs have asserted, and
many courts have permitted, medical monitoring claims, a trend,
which shows no signs of abating. And, the pragmatic and financial
incentives to plaintiffs' attorneys to bring these claims virtually en-
18. Id. at 823 n.10.
19. 525 A.2d 287 (NJ. 1987).
20. Id. at 290.
21. Id.
22. Ayers v.Jackson Township, 493 A.2d 1314, 1323 (NJ. Super. Ct. App. Div.
1985).
23. Id. (citing Coll v. Sherry, 148 A.2d. 481 (NJ. 1959)).
24. Ayers, 525 A.2d at 298, 312-13.
20001
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sure that the tide of medical monitoring claims will continue to
swell. Plaintiffs have advanced, and most assuredly will continue to
advance, a variety of public policy arguments favoring such awards.
For example, plaintiffs seeking recognition of a medical monitor-
ing remedy have cited the unfairness of requiring plaintiffs to bear
the costs of medical diagnostic examinations which, but for the de-
fendant's actions, they would not be compelled to undergo. 15 This
rationale obviously assumes that plaintiffs do indeed incur the ex-
penses associated with medical monitoring, and loses its initial in-
tuitive appeal if many plaintiffs choose not to seek medical atten-
tion in the wake of their exposure.
Plaintiffs also argue that advancing them the funds for obtain-
ing medical diagnosis furthers an important public health objec-
tive.'r Many people may not be able to afford such tests, the forego-
ing of which may lead to their discovery of an illness too late to take
advantage of treatment which could potentially save their lives or
mitigate the severity of their illness. 7
Plaintiffs further argue that requiring defendants to pay the
costs of anticipated medical monitoring may serve an important de-
211terrent function. Often, products liability and toxic tort plaintiffs
may be unable to prove that defendants' conduct caused them in-
jury. Long latency periods between exposure to a product and
the onset of illness increase the likelihood that defendants will have
left the pertinent market, material evidence will have vanished,
witnesses died, or memories lapsed. Furthermore, the longer the
latency period, the more likely that plaintiffs will have exercised
other lifestyle or occupational choices that arguably could have
contributed to their illness, rendering a verdict against the defen-
25. E.g., Hansen, 858 P.2d at 976 (noting that diagnostic examinations can be
expensive, and acknowledging the injustice of imposing such a financial burden
on plaintiffs exposed as a result of another's negligence); Ayers, 525 A.2d at 312
(stating that requiring plaintiffs, wrongfully exposed to toxic substances, to pay
their own medical expenses, is "inequitable").
26. Ayers, 525 A.2d at 311 (recognizing that medical monitoring damages are
"manifestly consistent with the public health interest in early detection and treat-
ment of disease.").
27. Hansen, 858 P.2d at 976.
28. E.g., In re Paoli R.R. Yard PCB Litig., 916 F.2d 829, 852 (3d Cir. 1990), cert.
denied sub nom. Gen. Elec. Co. v. Knight, 499 U.S. 961 (1991) ("[a]llowing plaintiffs
to recover the cost of this care deters irresponsible discharge of toxic chemicals by
defendants"), quoted with approval in Bower, 522 S.E.2d at 431; Potter v. Firestone
Tire & Rubber Co., 863 P.2d 795, 824 (Ca. 1993).
29. E.g., Ayers, 525 A.2d at 301-303 (acknowledging the many difficulties a
plaintiff must overcome to prove causation in a toxic tort case).
[Vol. 27:1
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dants less likely. For these reasons, plaintiffs assert that the current
tort system does not deter defendants who know, even though their
product may ultimately cause injury to a class of plaintiffs in the fu-
ture, they may not be held accountable because of the time lag.
Permitting medical monitoring awards upon a more lenient stan-
dard of proof provides defendants with an incentive to minimize
negligent conduct.30
Closely related to this argument is perhaps the most troubling
justification of medical monitoring damages. Some courts and
commentators have acknowledged the very real obstacles that
products liability and toxic tort plaintiffs face, and subtly suggested
that allowing plaintiffs to recover monitoring damages alleviates
some of the unfairness felt when their claims for enhanced risk or
for any physical injury that later develops fail." This seems to be an
impermissible commingling of disparate causes of action.
Finally, plaintiffs argue that providing for medical monitoring
damages may actually prove advantageous to defendants. A plain-
tiff who undergoes medical surveillance may discover an illness in
time to alleviate it, improving his or her prognosis and theoretically
reducing the value of any claim he or she may thereafter bring
against the defendants.32
IV. ARGUMENTS AGAINST MEDICAL MONITORING DAMAGES
Theoretically, deterring negligent defendants and ensuring
that nobody is denied access to health care because of lack of
30. Ayers, 525 A.2d at 312 (suggesting that permitting recovery for medical
monitoring expenses may subject polluters to significant liability, when proof of
causal connection between plaintiffs' exposure and defendant's tortious conduct is
strongest, thus providing a deterrent effect).
31. Redland Soccer Club, Inc. v. Dept. of the Army, 696 A.2d 137, 145 (Pa.
1997) (justifying medical monitoring awards which afford "toxic-tort victims, for
whom other sorts of recovery may prove difficult, immediate compensation for
medical monitoring needed as a result of exposure"); Slagel, supra note 1, at 852-
53 (commenting that the unlikelihood of a toxic tort plaintiffs recovering in a fu-
ture action, once injury manifests itself, renders pre-manifestation causes of action
more necessary). See also Terry Christovich Gay & Paige Freeman Rosato, Combat-
ting Fear of Future Injury and Medical Monitoring Claims, 61 DEF. COUNS. J. 554, 557
(1994) (observing that some courts permit medical monitoring awards "as a sort of
compromise to those arguably deserving plaintiffs" who are unable to recover un-
der other theories requiring a higher standard of proof).
32. E.g., Ayers, 525 A.2d at 312 ("The availability of a substantial remedy be-
fore the consequences of the plaintiffs' exposure are manifest may also have the
beneficial effect of preventing or mitigating serious future illnesses and thus re-
duce the overall costs to the responsible parties.").
2000]
7
Maskin et al.: Medical Monitoring: A Viable Remedy for Deserving Plaintiffs or T
Published by Mitchell Hamline Open Access, 2000
WILLIAM MITCHELL LAW REVIEW
funds, at a time when early detection could be most beneficial, are
noble goals. Nevertheless, several factors have the potential to
transform the medical monitoring concept into a redundant or
even ill-advised tool in the products liability and toxic tort context.
First, medical monitoring may be an entirely redundant remedy for
those who already have health insurance. Even assuming that
plaintiffs do indeed undergo the diagnostic examinations they
purport to seek, any money they recover will be a true windfall for
those whose health insurance already covers such costs. Most
medical monitoring plaintiffs have no present physical injury.
Rather, the injury for which they seek recompense is allegedly the
out-of-pocket expenses of reasonable medical monitoring. Where
plaintiffs' out-of-pocket expenses are nil, their recovery should be
also.3"
Second, the enormity of the universe of potential medical
monitoring plaintiffs is another very legitimate concern that should
counsel caution in future judicial acceptance of such awards. Ac-
cording to the United States Environmental Protection Agency, bil-
lions of pounds of hazardous chemicals are released into the air
each year. The EPA further reports that nearly 20 percent of the
U.S. population (approximately 40 million people) live within four
miles of a hazardous waste site on the National Priority List. Na-
tionwide, there are approximately 50,000 hazardous waste sites."
Between five and thirty-eight percent of all incidences of cancer
have been traced to workplace exposure to toxic substancesY.3  It
has been estimated that over twenty-one million Americans have
experienced significant exposure to asbestos.9 Almost everyone
comes into daily contact with second-hand smoke. Medical moni-
33. Friends, 746 F.2d at 822 n.7. Allowing recovery for medical monitoring
costs where such costs would be covered by health insurance or some other collat-
eral source seems contrary to the teachings of Friends, which accorded relief only
to those plaintiffs whose public health system would not cover any necessary diag-
nostic testing. Id.
34. Andrew R. Klein, Rethinking Medical Monitoring, 64 BROOKLYN L. REv. 1, 13
(Spring 1998) (citing PaulJ. Komyatte, Medical Monitoring Damages: An Evolution of
Environmental Tort Law, 23 COLO. LAW. 1533, 1533 (1994)).
35. Id.
36. Leslie S. Gara, Medical Surveillance Damages: Using Common Sense and the
Common Law to Mitigate the Damages Posed by Environmental Hazards, 12 HARv. ENVTL.
L. REv. 265, 265 (1988).
37. Id.
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toring claims have been predicated upon exposure to a wide variety
39 40
of potential hazards including cigarettes, landfills, workplace ra-
1. • 41 42 . . -43 . -- 44 - - -
diation, PCBs, termiticides, diet drugs, and contaminated wa-
ter,45 among others. Most people are thus legitimate potential
medical monitoring plaintiffs, a clear indication that the bounda-
ries of this potential tort remedy must be narrowly drawn to pre-
vent it spiraling out of control.46
Third, the universe of potential medical monitoring plaintiffs
seems vastly over-inclusive. For example, one study found that the
rate of lung cancer development among shipyard workers exposed
to asbestos was about 67 per million per year. Awarding the costs
of diagnostic examinations to one million workers, where only
sixty-seven will contract cancer in a given year, may be a grossly in-
efficient resource allocation. Obviously, we cannot predict with
certainty who, among exposed persons, will ultimately contract a
disease. For medical monitoring to serve its purpose, we do want to
ensure that as many as possible of those who do ultimately contract
a disease are given the opportunity to detect it as early as possible
to obtain prompt, comprehensive treatment. However, dispensing
large awards to those whose chances of illness as a result of a de-
fendant's conduct are small poses the real risk that little or no re-
sources will be available to compensate those who are truly injured,
39. Barnes v. Am. Tobacco Co., 161 F.3d 127, 130-31 (3d Cir. 1998), cert. de-
nied, 526 U.S. 1114 (1999).
40. Redland Soccer Club, Inc. v. Dept. of the Army, 55 F.3d 827, 834 (3rd Cir.
1995).
41. Day, 851 F. Supp. at 873.
42. In re Paoli R.R. Yard PCB Litig., 916 F.2d at 835.
43. Villari v. Terminix Int'l, Inc., 663 F. Supp. 727, 728 (E.D. Pa. 1987).
44. In re Diet Drugs Prods. Liab. Litig., 1999 U.S. Dist. LEXIS 13228, at *3.
45. Ayers, 461 A.2d at 185-86; Merry v. Westinghouse Elec. Corp., 684 F. Supp.
847, 848 (M.D. Pa. 1988); Potter, 863 P.2d at 800.
46. The scope of medical monitoring costs in products liability and toxic tort
cases is further compounded by the fact that many toxic substances may have the
potential to cause a wide variety of different ailments. That is, many substances to
which plaintiffs allege exposure do not cause a "signature disease." Exhaustive
testing for the future ramifications of the seemingly infinite number of ailments
which plaintiffs claim to suffer following their exposure presents defendants with
potentially significant liability. For example, in Hurd v. Monsanto Co., 164 F.R.D.
234, 237 (S.D. Ind. 1995), plaintiffs' exposure to PCBs precipitated such diverse
complaints asjoint pain, skin rashes, high cholesterol, nail fungus, loss of concen-
tration, numbness, endometriosis, headaches, sinus and stomach problems and
fear of cancer.
47. In re Hawaii Fed'I Asbestos Cases, 734 F. Supp. 1563, 1570 n.10 (D. Haw.
1990) (citing Kolonel, Cancer Occurrence in Shipyard Workers Exposed to Asbestos in
Hawaii, CANCER RESEARCH 45 (Aug. 1985)).
2000]
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in this case the sixty-seven cancer patients, by the time their injuries
manifest themselves.
Finally, permitting medical monitoring damages, as that claim
is presently implemented, may presage a dangerous loosening of
the causation requirement in more traditional causes of action, and
a complete eradication of the causation requirement in the medi-
cal monitoring context. That is, in medical monitoring cases,
plaintiffs need not prove that their exposure will actually cause a
future injury. Rather, they need only prove that the substance to
which they were exposed has the potential to cause a future injury.
4
8
In contrast, plaintiffs suing upon discovering a developed illness
must satisfy the more stringent burden of proving that the toxic
substance more probably than not did cause their injuries.
One commentator has suggested that plaintiffs who recover
for medical monitoring damages may be able to benefit from issue
preclusion should they later sue for any physical injury that later
develops. It is highly unlikely that any court would subscribe to
such an argument. Showing that a substance could cause a disease
is simply not the same as demonstrating that it in fact did. Allowing
demonstration of the former to substitute for proof of the latter is
as inappropriate as predicating a finding of criminal guilt upon a
finding of civil liability.
Nevertheless, it seems evident that the loose medical moni-
toring standard of proof, although not dispositive of traditional
physical injury claims, may spill over into traditional tort actions,
with courts gradually becoming more accepting of the less demand-
ing standard of proof accompanying medical monitoring claims.
For example, although courts fairly consistently prohibit recovery
for fear of future illness unless onset of such illness is more prob-
able than not, it is very possible that this requirement will likewise
be diluted, and recovery will be permitted for fear-based claims
where the feared illness could result from the toxic exposure. Such
an erosion of tort law's safeguards, if it transpires, may be one of
medical monitoring's most dangerous and significant legacies.
48. Potter, 863 P.2d at 824 (holding medical monitoring damages appropriate
where defendant's conduct has created a significant, but not necessarily likely, risk
of serious disease).
49. Johnson v. Celotex Corp., 899 F.2d 1281, 1285-86 (2d Cir. 1990).
50. Patricia E. Lin, Note Opening the Gates to Scientific Evidence in Toxic Exposure
Cases: Medical Monitoring and Daubert, 17 REV. LITIG. 551, 567-68 (Summer 1998).
[Vol. 27:1
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V. THE BASIC ELEMENTS OF A MEDICAL MONITORING CLAIM
Upon weighing these competing public policy objectives in fa-
vor of, and against, medical monitoring awards, the courts of most
states that have confronted the issue to date have, under certain
circumstances, recognized medical monitoring remedies.l Al-
though the precise interpretation of the elements of the cause of
action vary from state to state, one court has observed that the vari-
ous state and federal courts to have permitted medical monitoring
claims have moved toward, "relative consensus" on the necessary
elements." Most articulations are heavily influenced by the stan-
dard set forth in Ayers, which held that the cost of medical monitor-
ing is a compensable item of damages where the evidence demon-
strates through reliable expert testimony predicated upon the
significance and extent of exposure to chemicals, the toxicity of the
chemicals, the-seriousness of the diseases for which individuals are
at risk, the relative increase in the chance of onset of disease in
those exposed, and the value of early diagnosis, that such surveil-
lance to monitor the effect of exposure to toxic chemicals is rea-
53sonable and necessary.
For example, the Hansen court articulated the following ele-
ments a plaintiff must prove to qualify for medical monitoring
damages:
(i) exposure (ii) to a toxic substance (iii) which exposure
was caused by the defendant's negligence (iv) resulting in
an increased risk (v) of a serious disease, illness or injury
(vi) for which a medical test for early detection exists (vii)
and for which early detection is beneficial, meaning that a
treatment exists that can alter the course of the illness,
and (viii) the test has been prescribed by a qualified phy-
sician according to contemporary scientific principles.
Although various differences color a state's interpretation of the
elements, it seems unlikely that the basic foundation of the cause of
action will be shaken by courts facing it for the first time in the fu-
ture. Nonetheless, courts become more comfortable hearing medi-
cal monitoring claims, and as the ramifications of the remedy be-
51. Potter, 863 P.2d at 824-25; Hansen, 858 P.2d at 979-80; Burns v. Jaquays
Mining Corp., 752 P.2d 28, 33 (Ariz. Ct. App. 1988), rev. dismissed, 781 P.2d 1373
(Ariz. 1989).
52. Bower, 522 S.E.2d at 432.
53. Ayers, 525 A.2d at 312.
54. Hansen, 858 P.2d at 979.
20001
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become more apparent, it is inevitable that courts will experiment
with varying interpretations of the elements of the claim, in an at-
tempt to achieve a workable balance compensating all those and
only those who truly require medical monitoring.
A. Risk Of Injury
Most courts hold that, to satisfy the exposure requirement,
plaintiffs need not prove that they have a reasonable likelihood of
contracting the feared disease for which monitoring is sought.55
Rather, the plaintiffs need only prove that the exposure was suffi-
cient to increase their risk, such that medical monitoring is war-
ranted. Courts emphasize that no particular level of quantification
of increased risk must be established. 56 This lack of an articulated
minimum threshold is troubling, potentially permitting recovery to
plaintiffs whose risks are increased only microscopically.
57
Requiring that plaintiffs risk be significantly increased before
recovery is permitted would serve to limit the number of potential
claimants, and ensure that trivial claims do not overwhelm the judi-
cial system. Such an interpretation also appears unavoidable in
light of the requirement, imposed by most states, that the testing be
medically necessary. For example, in Ayers, although the court held
that, in order to recover, plaintiffs must demonstrate that the diag-
nostic examinations sought are "reasonable and necessary,, 59 it
nevertheless reinstated a medical monitoring award of over eight
million dollars, despite the Appellate Division's finding that plain-
tiffs' experts could not rule out the possibility that any increase in
risk to plaintiffs' health was "so microscopically small as to be mean-
ingless." It is difficult to understand how expensive medical moni-
55. Id.
56. Id.
57. The Ayers court permitted recovery of medical monitoring damages, de-
spite the Appellate Division's inability to rule out the probability that plaintiffs' in-
creased risk was so "microscopically small as to be meaningless." 493 A.2d 1314,
1323 (1985).
58. To limit the universe of potential plaintiffs, one commentator argues that
only those plaintiffs who can show that toxic exposure has more than doubled that
plaintiffs risk of disease should be entitled to recover medical monitoring dam-
ages. Klein, supra note 34, at 4. Such a proposition would reinvigorate some of
the causation requirement that seems to have been written out of the medical
monitoring arena.
59. Ayers, 525 A.2d at 312.
60. Id. at 297.
[Vol. 27:1
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toringt' can be a necessary response to a potentially microscopically
small risk.
An alternative means of screening out spurious claims, and en-
suring that medical monitoring damages are available only to those
at increased risk of future disease stemming from defendants' con-
duct, is to require that plaintiffs be suffering from a related injury
prior to bringing suit. The majority of courts have chosen not to
adopt this limiting mechanism. Instead, while recognizing that
the intervention of the tort system is inappropriate unless plaintiff• • 63
has been injured, those courts conclude that imposing on plain-
tiffs the costs of necessalz medical monitoring constitutes a pres-
ently compensable injury.
Other courts state that plaintiffs must demonstrate a present
65physical injury to recover medical monitoring damages. Never-
theless, in applying this principle, many appear to eviscerate any
meaningful distinction between injury and mere exposure. Thus,
the court in Askey v. Occidental Chemical Corporation 6purported to
require present injury, but defined injury as "the invasion of the
body by the foreign substance, with the assumption being that the
substance acts immediately upon the body setting in motion the
61. Plaintiffs in Ayers received an average of $24,921 for medical monitoring,
with awards ranging from $3,500 to $37,500. Slagel, supra note 1, at 869 n.129.
62. Burton v. R.J. Reynolds Tobacco Co., 884 F. Supp. 1515, 1522-23 (D. Kan.
1995); Burns, 752 P.2d at 33.
63. E.g., Redland Soccer Club, 55 F.3d at 846 n.8 (citing Gideon v. Johns-
Manville Sales Corp., 761 F.2d 1129, 1136 (5th Cir. 1985)) ("An actionable tort,
whether based on negligence or strict liability consists of two elements: a failure to
act in accordance with the standard of care required by law and a resultant in-
jury.. .However egregious the legal fault, there is no cause of action for negli-
gence... until there is 'actual loss or damage resulting to the interests of an-
other."').
64. Ayers, 525 A.2d at 304 ("The invasion for which redress is sought is the fact
that plaintiffs have been advised to spend money for medical tests, a cost they
would not have incurred absent their exposure to toxic chemicals."); see also
Friends, 746 F.2d at 826 ("It is difficult to dispute that an individual has an interest
in avoiding expensive diagnostic examinations just as he or she has an interest in
avoiding physical injury."); Hansen, 858 P.2d at 977 ("Although the physical mani-
festations of an injury may not appear for years, the reality is that many of those
exposed have suffered some legal detriment; the exposure itself and the concomi-
tant need for medical testing constitute the injury.").
65. Bowerman v. United Illuminating, No. X04CV 940115436S, 1998 Conn.
Super. LEXIS 3575, at *7-14 (Conn. Super. Dec. 15, 1998) (noting that a claim for
medical monitoring expenses does not stand alone, and refusing to award such
expenses to plaintiffs exposed to asbestos in the absence of proof of some action-
able physical injury).
66. 477 N.Y.S.2d 242 (N.Y. App. Div. 1984).
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67
forces which eventually result in disease .... Similarly, in Wer-
lein v. United States,"' the court found that "chromosomal breakage,
and damage to the cardiovascular and immunal systems" may suf-
fice to constitute injury. 69
Whatever route they take, it is imperative that courts remedy
this deficiency in future cases, and impose some more stringent re-
quirement 7° on the risk plaintiffs must show to recover medical
monitoring damages. That is the only way to ensure that truly de-
serving plaintiffs recover, and to increase the likelihood that future
funds will be available to compensate those who ultimately contract
a disease stemming from defendants' conduct.
B. Test Must Be Reasonably Medically Necessary ,
Most courts require plaintiffs to demonstrate that a reasonable
physician in the appropriate medical specialty would recommend
the monitoring regime they seek.71 Courts have generally allowed
physicians to take into account such practical considerations as the
burdensome frequency of the testing, its excessive price and the
risk of harm to the plaintiff in determining whether or not the test-
72ing would be recommended. Defendants seeking to mitigate
their liability for medical monitoring damages thus strive to pre-
sent, through expert testimony, both that the testing sought may
not be helpful, and that it may indeed be harmful.
As the tide of medical monitoring claims continues, which
seems inevitable, defendants must be prepared in future cases to
put plaintiffs to their proof, requiring that they demonstrate that
the diagnostic testing they seek does indeed have the potential to
improve their prognosis. Some commentators have observed a ju-
dicial bias that early detection is beneficial.73 Whether early detec-
67. Id. at 247 (citations omitted).
68. 746 F. Supp. 887 (D. Minn. 1990), vacated as moot, 793 F. Supp 898 (D.
Minn. 1992) (parties subsequently settled action).
69. Id. at 901.
70. For example, plaintiffs could be required to prove that their risk of injury
has been significantly increased, or that it is more probable than not that the
feared disease will actually result.
71. E.g., Carey v. Kerr-McGee Chem. Co., 999 F. Supp. 1109, 1120 (N.D. Ill.
1998) (medical monitoring must be shown to be necessary "to a reasonable degree
of medical certainty").
72. Hansen, 858 P.2d at 980.
73. E.g., Slagel, supra note 1, at 867 ("courts will probably continue to assume
that early detection is beneficial").
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tion is of benefit, at least for some severe illnesses, is subject to con-
siderable disagreement. One court for example, has concluded
that, "[d] elay in treatment almost invariably results in a more sen-" 174
ous prognosis. Others find little benefit in early detection, ob-
serving that the survival rate of cancer patients "has not increased
appreciably in the past forty years, despite improvements in both
diagnostic acumen and therapeutic skills.,
5
Clearly the value of early detection will be almost exclusively
dependent on the nature of the disease for which diagnosis is
sought. Courts in future cases cannot be allowed to rely on judicial
bias that early diagnosis necessarily improves treatment. Both
plaintiffs and defendants have an obligation to thoroughly explore
the medical literature, to present the most comprehensive study of
the efficacy or inefficacy of early diagnosis of the diseases for which
plaintiffs fear increased risk.76 For example, in Redland Soccer Club,7
the plaintiffs' expert acknowledged the limitations of current medi-
cal screening devices, commenting that the risks of some, such as
lung cancer screening, outweigh the potential benefits. 8 Such fac-
tors are appropriate to consider. Being required to pay the cost of
medical monitoring they will be forced to undergo is allegedly the
injury that gives plaintiffs standing to sue. Where plaintiffs are
unlikely to sustain that injury, because the testing is too burden-
some or dangerous, plaintiffs have no present injury for which to
be recompensed.
West Virginia, however, recently branched out from the path
of "relative consensus" on this issue, expressly permitting courts to
take the subjective concerns of the plaintiff into account in deter-
mining what tests are reasonably advisable.79  Thus, plaintiffs in
West Virginia courts can recover for prohibitively expensive diag-
74. Evers v. Dollinger, 471 A.2d 405, 409 n.4 (N.J. 1984); see also Bower, 522
S.E.2d at 431 (noting the value of early diagnosis for many cancer patients).
75. Slagel, supra note 1, at 868 n.118 (citing Parver, Defense of Delayed Diagnosis
and Treatment of Breast Cancer, 30 MED. TRIALQ. 34, 36-37 (1983)).
76. Id. at 869 n.121 (noting that defendants have argued almost exclusively
that medical monitoring damages should not be awarded in the absence of pre-
sent physical injury, to the exclusion of other arguments, such as the inefficacy of
early diagnosis).
77. 55 F.3d 827 (3d Cir. 1995).
78. Id. at 848.
79. Bower, 522 S.E.2d at 433 (" [T]he requirement that diagnostic testing must
be medically advisable does not necessarily preclude the situation where such a
determination is based, at least in part, upon the subjective desires of a plaintiff
for information concerning the state of his or her health").
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nostic testing that a doctor would not ordinarily recommend, and
are then free to spend the money on other purposes, merely be-
cause they express unassauged fears about their future health. This
dilutes the medical monitoring standard too far, hopelessly con-
founding it with the fear-of-future-illness cause of action. The
medical monitoring remedy is designed to reimburse plaintiffs for
reasonable medical diagnostic examinations-what is or is not rea-
sonable should be ascertained by an expert with appropriate medi-
cal knowledge, uninfluenced by a plaintiff with no medical experi-
ence.
C. Testing Must Be Different Than Prudent Person Would Ordinarily
Undergo
Before defendants should be required to pay for medical
monitoring, plaintiffs must demonstrate that the need for medical
monitoring is fairly traceable to defendants' conduct. Thus, defen-
dants should not be required to pay for screening recommended
for the general population even in the absence of exposure to de-
fendants' toxic substance,8 ° or for screening recommended in light
of plaintiffs' pre-existing conditions.
8'
Both of these considerations are highly fact dependent and
require thorough analysis of the available medical proof. In one
recent case 8' defendants presented an expert who opined that the
only types of cancers for which screening tests may be beneficial are
cervical, colon and breast cancer."3 The expert further stated that
no evidence suggested that plaintiffs' exposure to radiation had in-
creased their risk of cervical cancer, therefore such screening
should not be deemed medically advisable for these particular
plaintiffs.84 Further, according to this expert, all individuals are en-
couraged to receive screening for colon cancer, regardless of radia-
tion exposure and breast cancer screening is routinely recom-
mended for all women over forty. 8' Thus, according to defendants,
no medical screening procedures were available for plaintiffs that
86were not recommended for the population as a whole. Although
80. Potter, 863 P.2d at 825.
81. Id. at 826.
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the court found sufficient questions of fact on the propriety of
medical monitoring to deny defendants' motion for summary
judgment, this case provides an illustration of the analysis of what
testing, illness-by-illness, is generally recommended, in which plain-
tiffs and defendants litigating medical monitoring claims must en-
87gage.
A similar analysis must be undertaken with respect to testing
which is already medically required by plaintiffs' pre-existing condi-
tions or personal risk factors, such as smoking. Just as defendants
have not caused plaintiffs any out-of-pocket loss if the testing plain-
tiffs seek is recommended for the general population even in the
absence of exposure, so have defendants caused no additional out-
of-pocket loss if such testing would be recommended anyway based
on plaintiffs' personal health and risk factors. The paucity of dis-
cussion on this element in the reported cases suggests that this po-
tentially important avenue is vastly underutilized by defendants,
and could be a potent weapon in future cases. For example, the
defendants in Potter asserted this defense, successfully arguing that
they should not be responsible for the costs of medical monitoring
that plaintiffs' own lifestyle choices made reasonably necessary.""
All Potter plaintiffs were long-time cigarette smokers, seeking
medical monitoring damages for their exposure to contaminated
water, despite the fact that cigarette smoke was found to contain
approximately 2,500 times the benzene concentration of the con-. 89
taminated water. It seems that the Potter plaintiffs' fears of future
disease from the contaminated water were perhaps fuelled by the
fact that this was a risk they had not elected to take, which they did
not fully understand, whereas the risks from smoking may have
seemed less frightening because it was a risk which the plaintiffs
had chosen, and could, to some degree, control.
Defendants should be able to effectively demonstrate to ju-
ries that such attitudes do not comport with common sense or the
scientific evidence, and minimize recovery for risks which are min-
iscule in comparison with risks which plaintiffs already willingly
run.
87. Carey, 60 F. Supp. 2d at 811-13; see also Barnes, 161 F.3d at 155 (granting
summaryjudgment against plaintiff smoker, because the regular physical examina-
tions and cardiovascular risk assessments she sought are part of a normally pre-
scribed regime, even absent cigarette exposure).
88. Potter, 863 P.2d at 826 n.31.
89. Id. at 825.
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D. Early Diagnosis Must Be Beneficial
The majority of states explicitly require that a plaintiff demon-
strate that early diagnosis will be beneficial. One commentator,
approving of this requirement, aptly noted that where no treatment
currently exists, "early diagnosis merely lengthens the time over
which a person knows he suffers from the disease, but does nothing
to alter the natural history of the condition, or the ultimate fatal-
ity."91 One court added the more stringent requirement that not
only must treatment be available, but treatment must be more effi-
cacious if administered early, before the disease becomes obvious. 92
Otherwise, "there is no cause of action because medical monitoring
cannot fulfill its purpose. '
In this respect also, the recent West Virginia decision, Bower v.
Westinghouse Electric Corporation,94 abandons this prevailing view, per-
mitting recovery of medical monitoring damages even where no
treatment is available for the disease for which the plaintiff seeks
monitoring.95 The Bower court provided two principal rationales
for its decision. First, the constant advances of medical science
96swayed the court. Just because a treatment regimen is not pres-
ently available does not mean that one will not become available
within the plaintiffs lifetime. 97 For this reason, the court expressed
unwillingness to be constrained by the "static requirement" that
treatment be presently available. 9 While the Bower court is correct
to acknowledge that medical science is continually breaking new
frontiers, surely the preferred judicial response to this is to allow a
plaintiff, who fears he or she will contract a disease for which no
treatment currently exists, to sue for surveillance damages if and
when a treatment becomes available.
Courts have expressed willingness to entertain medical
90. E.g., Hansen, 858 P.2d at 979 (stating that plaintiff must show that a
treatment exists that can alter the course of the illness); Potter, 863 P.2d at 825
(noting that courts must take into account the clinical value of early detection and
diagnosis).
91. George W.C. McCarter, Medical Sue-Veillance: A History and Critique of the
Medical Monitoring Remedy in Toxic Tort Litigation, 45 RUTGERS L. REV. 227, 280
(Winter 1993) (citing Michael Alderson, OCCUPATIONAL CANCER 182 (1986)).
92. Hansen, 858 P.2d at 979-80.
93. Id. at 980.
94. 522 S.E.2d 424 (W. Va. 1999).
95. Id. at 432-34.
96. Id.
97. Id. at 434.
98. Id. at 433-34.
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monitoring suits, presently barred because no diagnostic testing is
available, if such testing is later developed.99 The Bower court ap-
peared not to consider such a course where testing is available but
where no treatment currently exists. Bower seems to have identified
a legitimate issue but chosen the wrong solution.
Requiring defendants to subsidize monitoring for an illness
for which treatment may become available will inevitably mean that
defendants will end up paying for monitoring for illnesses for
which treatment does not become available, a gross waste of re-
sources. Rather than indiscriminately awarding damages in the
hope that treatment is later developed, courts addressing this issue
in the future should only permit plaintiffs to bring a medical moni-
toring suit if and when a treatment is developed.
More interestingly, the Bower court justified its decision that
even where no treatment exists, plaintiffs should nevertheless be
entitled to damages, because:
One thing that.. .a plaintiff might gain [even in the
absence of available treatment] is certainty as to his fate,
whatever it might be. If a plaintiff has been placed at an
increased risk for a latent disease through exposure to a
hazardous substance, absent medical monitoring, he
must live each day with the uncertainty of whether the
disease is present in his body. If, however, he is able to
take advantage of medical monitoring and the monitor-
ing detects no evidence of disease, then, at least for the
time being, the plaintiff can receive the comfort of peace
of mind. Moreover, even if medical monitoring did de-
tect evidence of an irreversible and untreatable disease,
the plaintiff might still achieve some peace of mind
through this knowledge by getting his financial affairs in
order, making lifestyle changes, and, even perhaps, mak-
ing peace with estranged loved ones or with his religion.
Certainly, these options should be available to the inno-
cent plaintiff who finds himself at an increased risk for a
serious latent disease through no fault of his own.100
99. Hansen, 858 P.2d at 979 n.12 (noting that plaintiffs, for whom no diagnos-
tic test is currently available, have the right to sue for medical monitoring when
such testing becomes available in the future, provided the other elements of the
cause of action are met).
100. Bower, 522 S.E.2d at 434 (citing Bourgeois v. A.P. Green Indus., Inc., 716
So. 2d 355, 363 (La. 1998) (Calogero, C.J., concurring)).
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The Bower court is certainly anomalous in permitting recovery
in the absence of a currently available treatment for the feared dis-
ease. Because such an approach is so clearly inconsistent with the
articulated goals of medical monitoring, courts in future cases
should not follow the lead Bower offers.
Medical monitoring is intended to provide plaintiffs with an
opportunity to seek treatment for diseases where early detection
may be beneficial. Where no treatment exists, early detection sim-
ply is of no benefit. The alleged benefits identified by the Bower
court of making peace with loved ones and religion are spurious at
best. Most people do not have the luxury, if indeed it is one, of
knowing with precision when they are going to die. Allowing plain-
tiffs this highly questionable luxury would put them in a position
that it is likely they would not have enjoyed but for their medical
monitoring award, seemingly at unfair expense to defendants. Re-
fusing medical monitoring expenses where no treatment exists
seems to be a fairly logical way to limit potentially huge awards to
plaintiff classes while still providing medical examinations to those
for whom they would be beneficial.
VI. POTENTIAL FOR ABUSE IN THE AwARD OF LUMP SUM MEDICAL
MONITORING DAMAGES
Where a fact-finder has determined that plaintiffs merit medi-
cal monitoring relief, two principal methods exist to structure the
award. Plaintiffs may be awarded traditional damages, representing
the anticipated costs of medical tests that an expert deems to be
reasonably medically necessary. Alternatively, a court may establish
a fund, administered either by the court or an independent agency,
from which plaintiffs may seek reimbursement for testing they can
prove they underwent. Medical monitoring funds, as opposed to
lump-sum awards, are becoming more common, both because of a
growing judicial recognition that the fund mechanism is less sus-
ceptible to abuse than lump-sum damages, and because class certi-
fication may be appropriate only where injunctive relief is sought.
Defendants in future cases should vigorously contest the award
of lump-sum damages, the disadvantages of which are evident.
Most plaintiffs seeking medical surveillance costs are not currently
suffering from any diagnosable disease resulting from defendants'
conduct. Otherwise, they would generally be seeking compensa-
tion for the disease itself, rather than the more meager costs of de-
tecting it. The incentive for healthy plaintiffs to carefully hoard
[Vol. 27:1i
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their award, and faithfully spend it on periodic medical examina-
tions to detect an illness they will in all likelihood never contract,
seems negligible. °1 The far more enticing alternative, in most
cases, will be to put the money towards a new home, car or vaca-
tion. Visiting a physician is not something many people wish they
could afford to do more often.
Indeed, that lump sum medical monitoring awards are
unlikely to be used for their intended purpose seems to be one les-S 102
son we can draw from Ayers. One commentator, critical of the
theoretical prudence of medical monitoring awards, contacted sev-
eral dozen of the Ayers plaintiffs, who had shared in the $8,204,500
medical monitoring award. 03 Only three responded to a question-.... 104
naire probing the uses to which they had put their award. The
exceedingly small sample size obviously reduces the ability to ex-
trapolate from the study, but the findings are intuitive: One plain-
tiff spent his award on a new house, and none of the three reported
seeing a physician any more frequently than they had before their
lawsuit.'°3
Other compelling anecdotal evidence lends support to the no-
tion that presently healthy plaintiffs are unlikely to spend medical
monitoring awards on their intended purposes. In Hansen v. Moun-
tain Fuel Supply Co.,'or plaintiffs sought medical monitoring costs fol-
lowing workplace exposure to asbestos. 07 Almost seven years after
learning of their exposure, plaintiffs had submitted to only pre-
liminary examinations, revealing no illness traceable to their expo-
sure, but otherwise had undergone no further medical testing 1
s
The fact that none had undergone testing over a period of almost
seven years casts grave suspicion over their assertions that they
would use any medical monitoring sums awarded for their stated
101. Klein, supra note 34, at 24-25. As one commentator points out, logic dic-
tates that the risk that plaintiff will spend a medical monitoring award on some-
thing other than medical monitoring increases as his or her enhanced risk de-
creases.
102. Klein, supra note 34, at 25 n.111 (citing 2 ALI ENTERPRISE RESPONSIBILITY
FOR PERSONAL INJURY 379 n.59 (1991)), wherein ALl reporters concluded that the
plaintiffs in Ayers ultimately spent their medical monitoring awards on other unin-
tended purposes).
103. McCarter, supra note 91, at 258 n.158.
104. Id.
105. Id.
106. 858 P.2d 970 (Utah 1993).
107. Id. at 972-73.
108. Id. at 973.
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purpose. Although it is conceivable that plaintiffs' lack of testing
was attributable to their financial inability to pay for such tests, or
perhaps to the long latency period of asbestos-related diseases, it is
at least as likely that plaintiffs were less than concerned about
medical monitoring, and any such damages awarded to them would
have been a windfall."
0
Similarly, one commentator"' offers several representative ex-
cerpts of cross-examination testimony in which toxic tort plaintiffs,
seeking medical monitoring damages, were questioned about the
extent to which they had availed themselves of medical monitoring
opportunities to which they already had access."' Many had taken
little initiative to utilize what monitoring opportunities were al-
ready available to them. For example, several of the plaintiffs had
consulted their physician on numerous matters preceding the trial,
but had never mentioned the dioxin exposure for which they now
sought monitoring. Another plaintiff received free physical exami-
nations at his workplace but never sought an examination tailored
to his dioxin exposure.113
Plaintiffs who choose not to avail themselves of medical ex-
aminations before trial are highly unlikely to spend any damages
they receive on medical monitoring. Careful cross-examination on
the diagnostic examinations and medical care available to plaintiffs,
and the extent to which they have availed themselves of such care,
should thus be a critical element of any defense strategy in future
cases.
In response to these concerns, many courts have expressed a
preference for equitable remedies as opposed to traditional dam-
age awards, 1 4 a trend which seems likely to continue. In Hansen,
109. Id.
110. Id. at 982.
111. McCarter, supra note 91, at 257-58 & n.158.
112. Id.
113. McCarter, supra note 91, at 270-71 & n.212.
114. E.g., Day, 851 F. Supp. at 886 ("The use of the Courts [sic] injunctive
powers to oversee and direct medical surveillance is vastly superior to a lump sum
monetary payment.") (citation omitted); Bower, 522 S.E.2d at 434 ("While there
are situations where utilization of such [medical monitoring] funds may be bene-
ficial, we do not presently see a need to constrain the discretion of the trial courts
to fashion appropriate remedies in cases such as these.") (citation omitted); Ayers,
525 A.2d at 313-14 ("[T]he use of court-supervised funds.., rather than lump-
sum verdicts, may provide a more efficient mechanism for compensating plain-
tiffs.") ("Although there may be administrative and procedural questions in the
establishment and operation of [a medical monitoring fund], we encourage its use
by trial courts in managing mass-exposure cases.").
[Vol. 27:1
22
William Mitchell Law Review, Vol. 27, Iss. 1 [2000], Art. 18
http://open.mitchellhamline.edu/wmlr/vol27/iss1/18
MEDICAL MONITORING
the court took the logical next step and prohibited the award of
medical monitoring damages, payable in a lump-sum or other-
wise." l5 Rather, Hansen announced that courts must fashion an eq-
uitable remedy, such as requiring the defendant to establish a trust
fund, from which diagnostic expenses can be drawn, or pay for in-
surance to cover plaintiffs' future medical monitoring expenses.16
The approach advocated by Hansen seems correct and should
be adopted more frequently by courts attempting to curb the po-
tential for abuse in the medical monitoring context. Appropriate
equitable remedies provide all the advantages of traditional dam-
ages, are the more economically efficient of the two primary alter-
natives, and are in better harmony with the purported goals of the
cause of action. For example, establishing a medical monitoring
fund furthers the public health objective, encouraging plaintiffs to
safeguard their health by denying them the temptation to spend
the money in other ways. Furthermore, a fund provides deter-
rence, but not over-deterrence, as a defendant is required to pro-
vide compensation only for diagnostic examinations to which plain-
tiffs actually submitted. 18 And, such a remedy eliminates windfall
awards, as plaintiffs do not receive "reimbursement" for expenses
they did not incur, or which were covered by a collateral source,
such as health insurance. Additionally, an equitable remedy serves
to narrow the pool of potential plaintiffs, as only those sufficiently
concerned about the ramifications of their exposure obtain re-
lief. "9
As more and more plaintiffs seek medical monitoring dam-
ages, courts need to be aware of the real possibility that the remedy
they fashion will require defendants to pay for medical expenses
that in all likelihood will never be incurred. Limiting recovery to a
medical fund is an appropriate way for courts to take the interests
of both plaintiffs and defendants into account.
115. Hansen, 858 P.2d at 982.
116. Id.
117. Ayers, 525 A.2d at 314.
118. E.g., Day, 851 F. Supp. at 886-87 (observing that medical monitoring
funds serve to limit liability of defendants to expenses actually incurred).
119. McCarter, supra note 91, at 255-56 (noting two public policy considera-
tions: "(1) a person will not lightly submit to such [medical monitoring] proce-
dures and so should not be lightly compensated for them, and (2) when such pro-
cedures are indeed 'medically necessary', a person should be encouraged to
undergo them, despite the associated risk and inconvenience"). The author con-
cludes that awarding traditional monetary damages in medical monitoring cases
ignores both truths. Id.
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The realities of the class action mechanism may further serve
to shift the focus of medical monitoring to equitable as opposed to
traditional legal remedies. Federal Rule of Civil Procedure 23 gov-
erns class certification in federal courts. Under that rule, a party
seeking class certification must satisfy all four prerequisites of Rule
23(a)12 and any one of the subparts of Rule 23(b). Early toxic tort
class actions predominantly sought certification under 23(b) (3),121
under which the putative class must show that issues of fact and law
common to the class predominate over issues affecting only indi-
vidual class members, and that the proposed class action is superior
to other available methods for the fair and efficient adjudication of
the controversy.122 The burdens of Rule 23(b) (3) cannot easily be
met in the toxic tort and products liability context where individual
issues abound. 12  Plaintiffs' prior health history, degree, type and
duration of exposure, and personal risk factors such as smoking
and prior occupational exposure raise individualized issues.
120. Fed. R. Civ. P. 23(a) (1998) (requiring that a party seeking certification
demonstrate that: 1) the class is so numerous that the joinder of all members is
impracticable; 2) there are questions of law or fact common to the class; 3) the
claims or defenses of the representative parties are typical of those of the class; and
4) the class representatives will fairly and adequately protect the interests of the
class).
121. Charles W. Schwartz & Lewis C. Sutherland, Toxic Tort Symposium: Class
Certification for Environmental and Toxic Tort Claims, 10 TUL. ENVTL. L.J. 187, 192
(Summer 1997).
122. Fed. R. Civ. P. 23(b)(3) (1998).
123. Indeed, the 1966 Advisory Committee Notes clarifying Rule 23(b) (3) ex-
pressed the view that the class action device was not encouraged in mass tort cases.
Fed. R. Civ. P. 23(b) (3) Advisory Committee Notes (1966) ("A 'mass accident' re-
sulting in injuries to numerous persons is ordinarily not appropriate for a class ac-
tion because of the likelihood that significant questions, not only of damages but
of liability and defenses to liability, would be present, affecting the individuals in
different ways. In these circumstances an action conducted nominally as a class
action would degenerate in practice into multiple lawsuits separately tried.") (cita-
tions omitted).
124. Amchem Prods., Inc. v. Windsor, 521 U.S. 591, 591 (1997) (affirming re-
fusal to certify class of asbestos plaintiffs where plaintiffs had been exposed to dif-
ferent products in different ways for different time periods, with different health
ramifications); In reAm. Med. Sys., Inc., 75 F.3d 1069, 1081 (6th Cir. 1996) (decer-
tifying class of penile prosthesis recipients, where plaintiffs received different
products and experienced different ailments); In re Tetracycline Cases, 107 F.R.D.
719, 730, & 733-36 (W.D. Mo. 1985) (holding differences in chemical composition
of the drug ingested, knowledge of prescribing physician and reason for taking the
medication precluded class certification, even under 23 (c) (4) (A), whereby a class
action may be maintained with respect to discrete issues); see also Baker v. Wyeth-
Ayerst Labs. Div., 992 S.W.2d 797, 801 (Ark. 1999) (affirming denial of certifica-
tion of class of diet-drug users, under state class action rule, where plaintiffs had
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Similarly, defendants' conduct and the state-of-the-art generally will
have changed over time, detracting from common issues where
plaintiffs were exposed over a period of time, rather than in one
discrete incident. Tx- 7 126
In Amchem Products, Inc. v. Windsor, the Supreme Court ad-
dressed the propriety of certification of a class containing poten-
tially "hundreds of thousands, perhaps millions" of people exposed
to asbestos either occupationally or through occupational exposure
of a family member, and spouses or family members of such per-
sons.127 Affirming the Third Circuit's refusal to certify this "sprawl-. ,, 128
ing" class, the Court adopted much of the Third Circuit's analysis
of the predominance requirement, in a decision, which will have
far-reaching implications for mass tort cases in the future:
Class members were exposed to different asbestos-
containing products, for different amounts of time, in
different ways, and over different periods. Several class
members suffer no physical injury or have only asympto-
matic pleural changes, while others suffer from lung can-
cer, disabling asbestosis, or from mesothelioma... Each
has a different history of cigarette smoking, a factor that
complicates the causation inquiry.
The [exposure-only] plaintiffs especially share little
in common, either with each other or with the presently
injured class members. It is unclear whether they will
contract asbestos-related disease and, if so, what disease
each will suffer. They will also incur different medical
expenses because their monitoring and treatment will
depend on singular circumstances and individual medi-
cal histories. "9
different prior medical histories, the drugs were prescribed by different doctors,
with differing knowledge of the drugs' risks, plaintiffs themselves had differing
knowledge of the risks, and took the drug for different durations, in different
combinations, causing different physical symptoms).
125. But seeYslava v. Hughes Aircraft Co., 845 F. Supp. 705, 711-13 (D. Ariz.
1993) (certifying medical monitoring class under Rule 23(b) (2) but noting that
class certification under 23(b) (3) would also have been appropriate, finding that
differences in the amount of allegedly contaminated water consumed by each
plaintiff, changing water distribution patterns, variations in defendant's conduct
over time and plaintiffs' individual medical histories did not defeat commonality).
126. 521 U.S. 591, 591 (1997).
127. Id. at 591.
128. Id. at 594.
129. Id. at 624 (citation omitted).
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Although the Amchem Court acknowledged that "mass tort
cases arising from a common cause or disaster may, depending on• • • ,,130 -
the circumstances, satisfy the predominance requirement, it is
clear that 23(b) (3) is an avenue which has been closed to many fu-
ture mass-tort plaintiffs.
In response, many plaintiffs have recast their medical monitor-
ing claims, seeking to bring them within the purview of Rule
23(b) (2), which permits class certification where all four require-
ments of Rule 23(a) are satisfied, and "the party opposing the class
action has acted or refused to act on grounds generally applicable
to the class, thereby making appropriate final injunctive relief or
corresponding declaratory relief with respect to the class as a
whole".' 3 ' Rule 23(b) (2) does not require that plaintiffs meet the
predominance and superiority standards, which may make
23(b) (2) a more viable option for toxic tort plaintiffs seeking class• . 132
status for medical monitoring claims. Certification may not be
granted under this subpart where "the appropriate final relief re-
lates exclusively or predominantly to money damages. '  Thus,
whether a class can be maintained under Fed. R. Civ. P. 23(b) (2)
requires close examination of the remedy sought. "When 'the re-
alities of the litigation' demonstrate that the suit has been brought
primarily for money damages, it may not be maintained as a (b) (2)
class action."'4 Clearly, a traditional monetary award, approximat-
ing the cost of reasonably necessary medical examinations, cannot
support a 23(b) (2) class. Where plaintiffs seek establishment of a
medical monitoring fund, however, some have been willing to cate-
gorize the relief requested as injunctive,1 such that a 23(b) (2)
130. Id. at 625.
131. Fed. R. Civ. P. 23(b)(2).
132. But see Barnes, 161 F.3d at 142-43 (observing that while 23(b) (2) class ac-
tions have no formal predominance or superiority requirements, they may never-
theless require more cohesiveness than a 23(b) (3) class, because, unlike 23(b) (3)
actions, 23(b)(2) has no opt-out provision).
133. Fed. R. Civ. P. Rule 23(b)(2) Advisory Committee Notes.
134. Gibbs v. E.I. DuPont De Nemours & Co., 876 F. Supp. 475, 481 (W.D.N.Y.
1995) (citations omitted).
135. Id. (holding that "[a] court-administered fund which goes beyond pay-
ment of the costs of monitoring an individual plaintiffs health to establish pooled
resources for the early detection and advances in treatment of the disease is in-
junctive in nature rather than 'predominantly money damages' and therefore is
properly certified under Rule 23(b) (2)"); Day, 851 F. Supp. at 887 (holding certi-
fication under Rule 23(b) (2) proper where plaintiffs sought medical monitoring
fund, over defendants' objections that such relief is not injunctive as it simply re-
quires defendants to finance the fund, and therefore is more properly character-
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class may be maintained."3
Assuming from past experience that many plaintiffs are less
than interested in receiving actual diagnostic examinations, but are
driven by the lump-sum awards that courts were formerly more
likely to indulge, it seems that the 23(b) (2) route may present
many of the same problems of wastefulness as were manifest under
23(b) (3). That is, if defendants are required to establish a moni-
toring fund, of which few plaintiffs avail themselves, defendants will
137incur significant costs, yet provide few attendant public health
benefits, leaving plaintiffs' counsel as the only real winners.
VII. LEGISLATIVE REACTION To COURT CREATED MEDICAL
MONITORING CLAIMS
In response to a Louisiana Supreme Court decision,13 holding
that recovery for medical monitoring damages was permitted not-
withstanding that plaintiffs suffered from no present physical in-
jury,139 the Louisiana legislature passed a statute requiring physical
injury as an essential element of a medical monitoring claim.
1 40
Such a course is in sharp contrast with the pronounced trend
141which dispenses with the physical injury requirement. Indeed,
requiring proof that plaintiff presently suffers from an exposure-
related injury seems contrary to the underpinnings of the remedy,
which was designed to provide presently healthy plaintiffs with the
opportunity of early diagnosis of a disease from which they, as yet,142 ..
do not suffer. Such a requirement imposes upon plaintiffs the
ized as a request for damages).
136. Other courts have disagreed, however, and refused to certify a 23(b) (2)
medical monitoring class under 23(b)(2). For example, in Thomas v. FAG Bear-
ings Corp., 846 F. Supp. 1400, 1404 (W.D. Mo. 1994), the court disregarded plain-
tiffs' attempts to "couch such [medical monitoring] damages in the guise of in-
junctive relief' and determined that the remedy plaintiffs sought was nothing
more than an exchange of money. Accordingly, class certification under 23(b) (2)
was denied.
137. Although waste may be minimized by returning unused monies to the de-
fendant after the expiration of the fund, this procedure may not always be fol-
lowed as courts have considerable flexibility over the implementation and me-
chanics of a medical monitoring fund. Moreover, even if unused funds are
returned to defendants, defendants will nevertheless have been deprived of their
use for the duration of the fund.
138. Bourgeois v. A.P. Green Indus. Inc., 716 So. 2d 355 (La. 1998).
139. Id. at 361-62.
140. LA. CIV. CODE. ART. 2315 (2000).
141. Bower, 522 S.E.2d at 429-30; Potter, 863 P.2d at 825.
142. Bocook v. Ashland Oil Co., 819 F. Supp. 530, 538 (S.D. W. Va. 1993). The
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burdensome expenses of financing their own medical monitoring
costs unless or until they exhibit physical symptoms, an injustice
which the cause of action was intended to remedy. Moreover, by
the time a plaintiff suffers from a physical injury, such that he or
143
she can bring suit, medical monitoring may be moot.
Nevertheless, the Louisiana statute provides an interesting
example of one method society may use in the future to rein in
medical monitoring claims if the courts relax the causation re-
quirement too much. It is unlikely, however, that most jurisdic-
tions will resuscitate the physical injury requirement, because it is
contrary to the underlying rationale of medical monitoring. More-
over, it remains to be seen whether such a statute will have any real
impact. It is entirely possible that the physical injury requirement
will be so loosely interpreted as to encompass mere exposure.144
The real import of the Louisiana statute lies in its example of
a swift, clear legislative response to curb the scope of the medical
monitoring remedy, in an attempt to compensate only those with
truly meritorious claims. It is likely that other states will seek to
achieve a similar objective legislatively, whether or not they use the
same means.
VIII. CONCLUSION
Clearly, the medical monitoring remedy arose from a noble
goal-that of ensuring that financial hardship does not deprive
plaintiffs facing enhanced risk of disease because of a defendant's
negligence, of the means of detecting and treating at its early stages
court stated
[T]his court cannot discern the purpose for requiring a plaintiff to also
be seeking compensation for present manifest physical injuries. The very
essence of toxic exposure cases is the contention that physical injuries
therefrom are presently indiscernible; instead the facts are latent. To re-
quire a plaintiff to assert a potentially nonviable claim to recover for such
presently indiscernible injuries in order to be able to assert a claim for fu-
ture medical monitoring would amount to elevating form over substance.
143. Medical monitoring may be beneficial, even after an injury has already
been detected, in cases where the injury plaintiff has incurred is indicative of in-
creased risk of a discrete disease for which monitoring is available. For example, a
plaintiff exhibiting pleural thickening may still benefit from monitoring for ashes-
tosis or mesothelioma. By the time plaintiff has detected symptoms of many other
diseases, however, medical surveillance may be of little or no value.
144. Askey v. Occidental Chem. Corp., 477 N.Y.S.2d 242, 247 (N.Y. App. Div.
1984), Werlein v. United States, 746 F. Supp. 887, 901 (D. Minn. 1990), vacated in
part by 793 F. Supp. 898 (D. Minn. 1992).
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a serious disease. Nevertheless, the cause of action has spread far
from its initial carefully-limited roots, and now threatens to become
so liberally interpreted as to be universal.
Whereas Friends permitted medical monitoring costs for a
discrete class of plaintiffs, the size of which was immediately ascer-
tainable, arising from a single incident which was likely to be the
proximate cause of any physical injury sustained by plaintiffs im-
mediately thereafter, courts now permit such claims to be brought
by sprawling classes of plaintiffs, whose toxic exposure may be min-
iscule, and whose alleged injuries, if any, could be the result of a
host of variables other than exposure to defendants' products.
Moreover, while Friends established a medical monitoring fund to
ensure that defendants paid only for tests, which were actually ad-
ministered, recent decisions have transformed the remedy into a
consolation prize for plaintiffs for whom success under traditional
tort theories is unlikely, and indiscriminately given significant
monetary awards to be spent with no strings attached. Finally,
Friends provided compensation only for those plaintiffs whose
medical expenses would not already be covered by a collateral
source. Recent decisions have not inquired into plaintiffs' health
insurance coverage, or the availability of workplace diagnostic test-
ing, allowing plaintiffs to be "reimbursed" for expenses never in-
curred.
Abandoning medical monitoring is not the answer. Properly
regulated, medical monitoring awards can mean the difference be-
tween life and serious illness or death to truly meritorious plaintiffs.
However, future courts must continue to struggle to ensure that
truly deserving plaintiffs, and only truly deserving plaintiffs, may
partake of the medical monitoring remedy. Courts should grow
more comfortable enforcing more stringent requirements, such as
demanding that plaintiffs show significant exposure and a signifi-
cantly increased risk of disease. For diseases where no treatment is
presently available, recompense should be flatly denied, as moni-
toring would do nothing to improve plaintiffs' prognoses.
Legislative narrowing of the remedy should be expected and
encouraged where courts demonstrate excessive liberality. Both
plaintiffs and defendants must come to grips with the often-
underdeveloped scientific evidence pertaining to risk of disease
and treatment options, and vigorously work to identify those for
whom the chance of disease is sufficiently enhanced that medical
monitoring is truly medically necessary. Otherwise, the medical
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monitoring claim will degenerate into tort law's most expensive
consolation prize.
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